10:16:27 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-11-13 Kvartalsrapport 2024-Q3
2024-08-27 Kvartalsrapport 2024-Q2
2024-05-08 Kvartalsrapport 2024-Q1
2024-05-02 Ordinarie utdelning LIFE 0.00 NOK
2024-04-30 Årsstämma 2024
2024-02-27 Bokslutskommuniké 2023
2023-11-14 Kvartalsrapport 2023-Q3
2023-08-23 Kvartalsrapport 2023-Q2
2023-05-11 Kvartalsrapport 2023-Q1
2023-05-08 Ordinarie utdelning LIFE 0.00 NOK
2023-04-18 Årsstämma 2023
2023-02-28 Bokslutskommuniké 2022
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-09 Ordinarie utdelning LIFE 0.00 NOK
2022-05-06 Årsstämma 2022
2022-04-21 Bokslutskommuniké 2021
2021-09-30 Extra Bolagsstämma 2021
2021-08-05 Kvartalsrapport 2021-Q2
2021-05-10 Ordinarie utdelning LIFE 0.00 NOK
2021-05-07 Årsstämma 2021
2021-04-20 Bokslutskommuniké 2020
2020-06-26 Årsstämma 2020
2020-06-01 Bokslutskommuniké 2019
2019-02-07 Split LIFE 4:1
2018-12-11 Extra Bolagsstämma 2018

Beskrivning

LandNorge
ListaEuronext Growth Oslo
SektorHälsovård
IndustriMedicinteknik
Lifecare är ett norskt bolag verksamma inom medicinteknik. Idag är bolaget specialiserade inom forskning och utveckling av diabetes. Produkterna är patenterade och används som glukosgivare. Mikrosensorerna injiceras under huden på patientens handled, och fungerar vidare som en realtidsuppdatering av glukosnivån i patienten. Utöver bidrar tekniken med larmsensor samt tillgång till historisk data över patientens glukosnivå. Bolaget etablerades under 2006 och har sitt huvudkontor i Bergen, Norge.
2024-02-14 08:00:00

Bergen, Norway, 14 February 2024: Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), has successfully finished the first and important step of software implementation and coding for the upcoming automated pilot production. In addition to this Lifecare has received confirmation of delivery of essential equipment.

Reference is made to Lifecare’s list of trigger events, as presented at the semi-annual report of August 20th 2023 and later investor communication. The launch of an automated production line by end of Q2 2024 is set as a major milestone.

PROGRESS ON SOFTWARE CUSTOMIZATION

The software from Zeiss that Lifecare purchased in October 2023 is essential to automate production with the Scanning Electron Microscopes (SEM) ordered from Carl Zeiss IQS Deutschland GmbH (Zeiss). The team at Lifecare NanoBioSensors in Reutlingen Germany is responsible for the specific software customization. When finalized and implemented the customized software will handle the automated pilot production of Lifecare’s nano pressure sensors on the sensor implants.

- We are happy to be able to finalize the first important step of our software customization program. Our team has always been optimistic that this is the right tool to produce our nanosensor-elements. Hence it is now satisfying to see we are getting the necessary confirmations that the programming is working as planned in this first stage of implementation, says CEO Joacim Holter at Lifecare.

PROGRESS ON PRODUCTION EQUIPMENT

The adaptation and coding of the software from Zeiss are just one of several things that can be confirmed these days. Lifecare has now also received confirmation that the delivery of key equipment for the upcoming automated pilot production is progressing according to the plan:

  • In November 2023 Lifecare placed the purchase order for a SEM from the German supplier Carl Zeiss AG. The SEM is a key component to manufacture Lifecare’s unique sensor for Continuous Glucose Monitoring applying osmotic pressure as the sensing principle. The Zeiss XB350 electron microscope is highly advanced and precise and especially suitable for the Lifecare’s automated production application.

Supplier has now confirmed the delivery of equipment in Q2 2024.

  • In December 2023 Lifecare placed the final purchase order for further automated production components; a BioScaffolder (“BS 3.3) and a customized Nano-Plotter (“NP 2.1”) from the German supplier GeSiM mbH. This equipment will be essential tools for the automated process of filling Lifecare’s proprietary and patented glucose-reactive chemical solution in the nanosized chambers of the sensors, also applying the nano-porous membranes to seal the chambers after filling.

Supplier has now confirmed the delivery of equipment in Q2 2024.

- There are several important pieces that have now fallen into place. The Lifecare organization has recently made successful appointments of key personnel such as CFO and Production Manager. The organization is now strengthened with additional key competences as more cornerstone equipment being delivered as planned. This is reassuring. We see that we are now really on the brink of automated pilot production and a new era for our sensor technology, says CEO Joacim Holter.